In addition, Suzanne I.S. Mosely and colleagues have demonstrated that NK (26.92%), CD4+ T (7.24%), and CD8+ T (5.04%) are indeed higher in immunotherapy-sensitive CT26-derived tumor models compared to others, including LL/2 [24]. This evidence concerns the gene DDX53 and neoplasm.